| 1.74 -0.27 (-13.43%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.54 | 1-year : | 5.03 |
| Resists | First : | 3.03 | Second : | 4.3 |
| Pivot price | 2.6 |
|||
| Supports | First : | 0.96 | Second : | 0.8 |
| MAs | MA(5) : | 1.96 |
MA(20) : | 2.44  |
| MA(100) : | 1.76 |
MA(250) : | 5.85 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 12.9 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 19.03 | Low : | 0.96 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MTVA ] has closed above bottom band by 11.7%. Bollinger Bands are 19.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.17 - 2.18 | 2.18 - 2.2 |
| Low: | 1.7 - 1.71 | 1.71 - 1.72 |
| Close: | 1.72 - 1.74 | 1.74 - 1.76 |
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Tue, 09 Jun 2026
MetaVia Shareholders Approve Equity Plan and Reverse Split - The Globe and Mail
Mon, 08 Jun 2026
MetaVia (MTVA) director awarded 17,186 RSUs vesting in 2027 - Stock Titan
Mon, 08 Jun 2026
MetaVia (MTVA) awards 17,186 stock units to board director - Stock Titan
Mon, 08 Jun 2026
MetaVia (MTVA) director gets 17,186 RSUs vesting in 2027 - Stock Titan
Mon, 08 Jun 2026
MetaVia (MTVA) director Jason Groves awarded 17,186 RSUs in equity grant - Stock Titan
Mon, 08 Jun 2026
MetaVia Inc. (MTVA) director receives 17,186-share restricted stock grant - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 34.5 (%) |
| Held by Institutions | 13.3 (%) |
| Shares Short | 69 (K) |
| Shares Short P.Month | 64 (K) |
| EPS | -4.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -65.3 % |
| Return on Equity (ttm) | -195.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|